AGLE-102 Demonstrates Compelling Efficacy & Safety in a Phase 1/2a Study in Recessive Dystrophic Epidermolysis Bullosa
- AGLE-102 showed meaningful improvements in wound healing and skin integrity in patients with recessive dystrophic epidermolysis bullosa (RDEB), indicating strong therapeutic potential
- The treatment was well tolerated across the study population, with no significant safety concerns or dose-limiting toxicities reported
- Phase 1/2a results support further development, demonstrating both biological activity and clinical benefit in this high unmet-need genetic disorder